Author: claimsbot

1. A compound represented by general formula (I):
a prodrug thereof, or a pharmaceutically acceptable salt thereof, wherein
R1 is a hydrogen atom or a lower alkyl group;
each of R2 and R3 is independently a hydrogen atom or a lower alkyl group;
each of R4, R5 and R6 is independently a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group;
R7 is a hydrogen atom or a lower alkyl group;
R8 is a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, an aryloxy group, an aralkyloxy group, a heteroaryl group, a hydroxy-lower alkyl group, a hydroxy group, a di(lower alkyl)amino group, a cyclic amino group, a di(lower alkyl)amino-lower alkyl group, a lower acyl group, a lower alkylsulfanyl group, a lower alkylsulfonyl group, a carboxy group, a lower alkoxycarbonyl group or an aralkyloxycarbonyl group,
or R7 and R8 are bonded together to form \u2014OCH2O\u2014 or \u2014CH\u2550CH\u2014CH\u2550CH\u2014;
R9 is a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a hydroxy-lower alkyl group, a hydroxy group, a lower alkoxy group, a cyano group, a lower alkylsulfonyl group, a lower alkylsulfonylamino group, \u2014COR10, -A1-COR10, or \u2014O-A2-COR10;
R10 is a hydroxy group, a lower alkoxy group or \u2014NR11R12,
each of R11 and R12 is independently a hydrogen atom, a lower alkyl group, a carboxy-lower alkyl group or a lower alkoxycarbonyl-lower alkyl group, or R11 and R12, together with the nitrogen atom to which they are bonded, form a cyclic amine;
A1 is a lower alkylene group or a lower alkenylene group;
A2 is a lower alkylene group;
Ar is a group represented by a formula:
or a heteroaryl group;
each of R13 and R14 is independently a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a hydroxy group, a lower alkylsulfonylamino group or a lower acylamino group, or when R13 and R14 are adjacent each other, then R13 and R14 are bonded together to form a group represented by \u2014NH\u2014C(O)\u2014NH\u2014, provided that when one of R13 and R14 is a hydrogen atom, then the other is not a hydroxy group; and
A is a bond, \u2014OCH2\u2014 or \u2014SCH2\u2014.
2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein
Ar is a group represented by a formula:
or a pyridyl group;
each of R13 and R14 is independently a hydrogen atom, a halogen atom, a hydroxy group, a lower alkylsulfonylamino group or a lower acylamino group, or when R13 and R14 are adjacent each other, then R13 and R14 are bonded together to form a group represented by \u2014NH\u2014C(O)\u2014NH\u2014.
3. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein
Ar is a group represented by a formula:
in which R15 is a lower alkyl group; and
A is a bond.
4. A compound represented by general formula (II):
or a pharmaceutically acceptable salt thereof, wherein
R1 is a hydrogen atom or a lower alkyl group;
each of R2 and R3 is independently a hydrogen atom or a lower alkyl group;
each of R4, R5 and R6 is independently a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group;
R7 is a hydrogen atom or a lower alkyl group;
R8 is a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a di(lower alkyl)amino group, a carboxy group, or a lower alkoxycarbonyl group;
R9 is a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a hydroxy-lower alkyl group, a hydroxy group, a lower alkoxy group, a cyano group, a lower alkylsulfonyl group, a lower alkylsulfonylamino group, \u2014COR10, -A1-COR10, or \u2014O-A2-COR10;
R10 is a hydroxy group, a lower alkoxy group or \u2014NR11R12;
each of R11 and R12 is independently a hydrogen atom, a lower alkyl group, a carboxy-lower alkyl group or a lower alkoxycarbonyl-lower alkyl group, or R11 and R12, together with the nitrogen atom to which they are bonded, form a cyclic amine;
A1 is a lower alkylene group or a lower alkenylene group;
A2 is a lower alkylene group; and
R15 is a lower alkyl group.
5. The compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein
R9 is \u2014COR10, or \u2014OCH2COR10; and
R10 is a hydroxy group or a lower alkoxy group.
6. The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein at least one of R2 and R3 is a hydrogen atom.
7. The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein R2 and R3 are a hydrogen atom.
8. The compound according to claim 7, or a pharmaceutically acceptable salt thereof, wherein
each of R4 and R5 is independently a hydrogen atom or a lower alkyl group; and R6 is a lower alkyl group.
9. The compound according to claim 7, or a pharmaceutically acceptable salt thereof, wherein
R4 is a hydrogen atom; and
each of R5 and R6 is independently a lower alkyl group.
10. The compound according to claim 7, or a pharmaceutically acceptable salt thereof, wherein
R4, R5 and R6 are a hydrogen atom; and
R8 is a halogen atom, a lower alkyl group, a lower alkoxy group, or a di(lower alkyl)amino group.
11. The compound according to claim 7, or a pharmaceutically acceptable salt thereof, wherein
R4, R5 and R6 are a hydrogen atom; and
R8 is a lower alkyl group.
12. The compound according to claim 1, a lower alkyl ester thereof, or a pharmaceutically acceptable salt thereof, selected from the group consisting of
4\u2032-{2-(1S,2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylaminophenyl)-1-methylethylaminoethoxy}-3\u2032,5\u2032-dimethylbiphenyl-4-carboxylic acid;
4\u2032-{2-(1S,2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylaminophenyl)-1-methylethylaminoethoxy}biphenyl-4-carboxylic acid;
4\u2032-{2-(R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylaminophenyl)ethylaminoethoxy}-2\u2032,6\u2032-dimethylbiphenyl-4-carboxylic acid;
(4\u2032-{2-(1S,2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylaminophenyl)-1-methylethylaminoethoxy}-3\u2032,5\u2032-dimethylbiphenyl-4-yloxy)acetic acid;
4\u2032-{2-(1S,2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylaminophenyl)-1-methylethylaminoethoxy}-2\u2032,6\u2032-dimethylbiphenyl-4-carboxylic acid;
(4\u2032-{2-(1S,2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylaminophenyl)-1-methylethylaminoethoxy}-2\u2032,6\u2032-dimethylbiphenyl-4-yloxy)acetic acid;
4\u2032-{2-(R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylaminophenyl)ethylaminoethoxy}-2-methylbiphenyl-4-carboxylic acid;
4\u2032-{2-(R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylaminophenyl)ethylaminoethoxy}biphenyl-3,4-dicarboxylic acid;
3-(N,N-dimethylamino)-4\u2032-{2-(R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylaminophenyl)ethylaminoethoxy}-biphenyl-4-carboxylic acid;
3-ethoxy-4\u2032-{2-(R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylaminophenyl)ethylaminoethoxy}biphenyl-4-carboxylic acid;
4\u2032-{2-(R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylaminophenyl)ethylaminoethoxy}biphenyl-4-carboxylic acid;
4\u2032-{2-(R)-2-hydroxy-3-(2-oxo-2,3-dihydro-1H-benzimidazol-4-yloxy)propylaminoethoxy}-3\u2032,5\u2032-dimethylbiphenyl-4-carboxylic acid; and
4\u2032-{2-(R)-2-hydroxy-3-(2-oxo-2,3-dihydro-1H-benzimidazol-4-yloxy)propylaminoethoxy}-3-isopropyl-3\u2032,5\u2032-dimethylbiphenyl-4-carboxylic acid.
13. A pharmaceutical composition which comprises, as an active ingredient, a compound of general formula (I):
or a pharmaceutically acceptable salt thereof, wherein
R1 is a hydrogen atom or a lower alkyl group;
each of R2 and R3 is independently a hydrogen atom or a lower alkyl group;
each of R4, R5 and R6 is independently a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group;
R7 is a hydrogen atom or a lower alkyl group;
R8 is a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, an aryloxy group, an aralkyloxy group, a heteroaryl group, a hydroxy-lower alkyl group, a hydroxy group, a di(lower alkyl)amino group, a cyclic amino group, a di(lower alkyl)amino-lower alkyl group, a lower acyl group, a lower alkylsulfanyl group, a lower alkylsulfonyl group, a carboxy group, a lower alkoxycarbonyl group or an aralkyloxycarbonyl group,
or R7 and R8 are bonded together to form \u2014OCH2O\u2014or \u2014CH\u2550CH\u2014CH\u2550CH\u2014;
R9 is a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a hydroxy-lower alkyl group, a hydroxy group, a lower alkoxy group, a cyano group, a lower alkylsulfonyl group, a lower alkylsulfonylamino group, \u2014COR10, -A1-COR10, or \u2014O-A2-COR10;
R10 is a hydroxy group, a lower alkoxy group or \u2014NR11R12,
each of R11 and R12 is independently a hydrogen atom, a lower alkyl group, a carboxy-lower alkyl group or a lower alkoxycarbonyl-lower alkyl group, or R11 and R12, together with the nitrogen atom to which they are bonded, form a cyclic amine;
A1 is a lower alkylene group or a lower alkenylene group;
A2 is a lower alkylene group;
Ar is a group represented by a formula:
or a heteroaryl group;
each of R13 and R14 is independently a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a hydroxy group, a lower alkylsulfonylamino group or a lower acylamino group, or when R13 and R14 are adjacent each other, then R13 and R14 are bonded together to form a group represented by \u2014NH\u2014C(O)\u2014NH\u2014, provided that when one of R13 and R14 is a hydrogen atom, then the other is not a hydroxy group; and
A is a bond, \u2014OCH2\u2014 or \u2014SCH2\u2014, and a pharmaceutically acceptable carrier.
14. A pharmaceutical combination comprising (A) a compound of general formula (I):
or a pharmaceutically acceptable salt thereof, wherein
R1 is a hydrogen atom or a lower alkyl group;
each of R2 and R3 is independently a hydrogen atom or a lower alkyl group;
each of R4, R5 and R6 is independently a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group;
R7 is a hydrogen atom or a lower alkyl group;
R8 is a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, an aryloxy group, an aralkyloxy group, a heteroaryl group, a hydroxy-lower alkyl group, a hydroxy group, a di(lower alkyl)amino group, a cyclic amino group, a di(lower alkyl)amino-lower alkyl group, a lower acyl group, a lower alkylsulfanyl group, a lower alkylsulfonyl group, a carboxy group, a lower alkoxycarbonyl group or an aralkyloxycarbonyl group,
or R7 and R8 are bonded together to form \u2014OCH2O\u2014 or \u2014CH\u2550CH\u2014CH\u2550CH\u2014;
R9 is a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a hydroxy-lower alkyl group, a hydroxy group, a lower alkoxy group, a cyano group, a lower alkylsulfonyl group, a lower alkylsulfonylamino group, \u2014COR10, -A1-COR10, or \u2014O-A2-COR10;
R10 is a hydroxy group, a lower alkoxy group or \u2014NR11R12,
each of R11 and R12 is independently a hydrogen atom, a lower alkyl group, a carboxy-lower alkyl group or a lower alkoxycarbonyl-lower alkyl group, or R11 and R12, together with the nitrogen atom to which they are bonded, form a cyclic amine;
A1 is a lower alkylene group or a lower alkenylene group;
A2 is a lower alkylene group;
Ar is a group represented by a formula:
or a heteroaryl group;
each of R13 and R14 is independently a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a hydroxy group, a lower alkylsulfonylamino group or a lower acylamino group, or when R13 and R14 are adjacent each other, then R13 and R14 are bonded together to form a group represented by \u2014NH\u2014C(O)\u2014NH\u2014, provided that when one of R13 and R14 is a hydrogen atom, then the other is not a hydroxy group; and
A is a bond, \u2014OCH2\u2014 or \u2014SCH2; and
(B) at least one member selected from the group consisting of an antiobesity agent, an antidiabetic agent, a hypolipidemic agent and a therapeutic agent for urinary dysfunctions other than a \u03b23-adrenoceptor agonist.
15. A method for treating obesity, diabetes mellitus, hyperlipidemia, depression, urinary dysfunctions, diseases caused by biliary calculus or biliary tract hypermotility, or diseases caused by intestinal hypermotility, which comprises administering an effective amount of a compound of general formula (I):
or a pharmaceutically acceptable salt thereof, wherein
R1 is a hydrogen atom or a lower alkyl group;
each of R2 and R3 is independently a hydrogen atom or a lower alkyl group;
each of R4, R5 and R6 is independently a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group;
R7 is a hydrogen atom or a lower alkyl group;
R8 is a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, an aryloxy group, an aralkyloxy group, a heteroaryl group, a hydroxy-lower alkyl group, a hydroxy group, a di(lower alkyl)amino group, a cyclic amino group, a di(lower alkyl)amino-lower alkyl group, a lower acyl group, a lower alkylsulfanyl group, a lower alkylsulfonyl group, a carboxy group, a lower alkoxycarbonyl group or an aralkyloxycarbonyl group,
or R7 and R8 are bonded together to form \u2014OCH2O\u2014 or \u2014CH\u2550CH\u2014CH\u2550CH\u2014;
R9 is a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a hydroxy-lower alkyl group, a hydroxy group, a lower alkoxy group, a cyano group, a lower alkylsulfonyl group, a lower alkylsulfonylamino group, \u2014COR10, -A1-COR10, or \u2014O-A2-COR10;
R10 is a hydroxy group, a lower alkoxy group or \u2014NR11R12,
each of R11 and R12 is independently a hydrogen atom, a lower alkyl group, a carboxy-lower alkyl group or a lower alkoxycarbonyl-lower alkyl group, or R11 and R12, together with the nitrogen atom to which they are bonded, form a cyclic amine;
A1 is a lower alkylene group or a lower alkenylene group;
A2 is a lower alkylene group;
Ar is a group represented by a formula:
or a heteroaryl group;
each of R13 and R14 is independently a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower aikoxy group, a hydroxy group, a lower alkylsulfonylamino group or a lower acylamino group, or when R13 and R14 are adjacent each other, then R13 and R14 are bonded together to form a group represented by \u2014NH\u2014C(O)\u2014NH\u2014, provided that when one of R13 and R14 is a hydrogen atom, then the other is not a hydroxy group; and
A is a bond, \u2014OCH2\u2014 or \u2014SCH2.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A remote displaying apparatus comprising:
a main body including a display configured to display an image wirelessly transmitted from an image pickup apparatus, and a connection section for attaching the main body to an attachment object; and
a belt configured to fix the main body and a user arm.
2. The remote displaying apparatus according to claim 1, wherein the main body further includes a record operation button to transmit an instruction of a start or an end of recording to the image pickup apparatus.
3. The remote displaying apparatus according to claim 2, wherein the main body further includes a first face, the display and the record operation button are on the first face, and the connection section is at a second face of the main body other than the first face.
4. The remote displaying apparatus according to claim 1, wherein the main body further includes a selection button used to select an item from a menu displayed on the display.
5. The remote displaying apparatus according to claim 1, wherein the main body further includes a notification section which lights up when the image pickup apparatus is in a recording state.
6. The remote displaying apparatus according to claim 1, wherein the main body further includes:
a record operation button to transmit an instruction of a start or an end of recording to the image pickup apparatus; and
a notification section to notify when the image pickup apparatus is in a recording state by pressing the record operation button.
7. The remote displaying apparatus according to claim 1, wherein the main body further includes a terminal configured to charge a battery of the remote displaying apparatus by linking an external device.
8. The remote displaying apparatus according to claim 7, wherein the terminal is covered.
9. The remote displaying apparatus according to claim 1, wherein the remote displaying apparatus is configured to connect with two or more image pickup apparatuses simultaneously and is configured to cause the image transmitted from one image pickup apparatus selected from the image pickup apparatuses to be displayed.
10. The remote displaying apparatus according to claim 1, wherein the main body further includes a sensor that senses an attitude of the remote displaying apparatus.
11. The remote displaying apparatus according to claim 1, wherein the main body further includes a sensor that senses an attitude of the remote displaying apparatus, and a direction in which the display is rotated based on a result of sensing by the sensor.
12. The remote displaying apparatus according to claim 1, wherein the main body further includes one or more side face operation sections.
13. The remote displaying apparatus according to claim 12, wherein the one or more side face operation sections are provided on one or more side faces along a first direction in which the display and a record operation button are arranged.
14. The remote displaying apparatus according to claim 13, wherein the side face operation sections are provided at positions not overlapping with each other along the first direction, when provided on opposite side faces respectively.
15. The remote displaying apparatus according to claim 1 further comprising:
a base plate configured to be interposed between the main body and the user arm when the remote displaying apparatus is worn on the user arm.

1. A method fabricating integrated circuits providing a desired operation using a plurality of masks, wherein each of said plurality of masks is used to control a corresponding one of a plurality of layers to form said integrated circuits, said method comprising:
incorporating a plurality of dummy stacks along with a functional block, said functional block providing said desired operation, each of said dummy stack providing a point of common connectivity on a plurality of metal layers comprised in said plurality of layers.
2. The method of claim 1, wherein said plurality of metal layers comprise all metal layers providing connectivity to elements contained in said functional block.
3. The method of claim 1, wherein each of said dummy stacks contain vias to provide said point of common connectivity.
4. The method of claim 1, further comprising fabricating said integrated circuits using masks designed according to said incorporating.
5. The method of claim 1, further comprising:
identify the connections required to be added and removed to implement a desired design change; and
redesign some of said plurality of masks to addremove identified connections using a dummy stack, wherein said dummy stack is connected to said functional block.
6. The method of claim 5, further comprising fabricating said integrated circuits using masks designed according to said redesign.
7. The method of claim 1, further comprising:
map to a common plane the area portions occupied by each of said plurality of metal layers in providing connectivity for elements forming said functional portion; and
identify unoccupied areas on said common plane,
wherein said incorporating incorporates said plurality of dummy stacks in said unoccupied areas.
12. A computer readable medium carrying one or more sequences of instructions for causing a system to implement computer aided design of an integrated circuit, wherein each of said integrated circuits comprise a plurality of metal layers used to implement a functional portion of said integrated circuit, wherein execution of said one or more sequences of instructions by one or more processors contained in said system causes said one or more processors to perform the actions of:
map to a common plane the area portions occupied by each of said plurality of metal layers in providing connectivity for elements forming said functional portion of said integrated circuit; and
identify unoccupied areas on said common plane,
wherein a plurality of dummy stacks are incorporate in said unoccupied areas.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. An image sensor with a spectrum sensor, comprising:
an image sensor region having a plurality of light-detection parts;
a spectrum sensor region located in the image sensor region; and
image signal processor analyzing, processing the image which is obtained by said image sensor region and the spectrum signal which is obtained by said spectrum sensor region,
wherein said spectrum sensor region comprises:
a first spectrum sensor region for obtaining a reference signal; and
a second spectrum sensor region for obtaining a spectrum signal of the object.
2-3. (canceled)
4. The image sensor with the spectrum sensor according to claim 3 claim 1, wherein the image signal processor comprises:
an image reception part receiving the image obtained in the image sensor region;
a reference signal reception part receiving a reference signal for checking a current lighting condition from the first spectrum sensor region;
a object spectrum signal reception part receiving from the second spectrum sensor region a spectrum signal of the object that passed the band pass filter; and
a computation part computing a reflection or transmission rate of the object with respect to each band of the band pass filter by comparing the spectrum signal of the object with the reference signal.
5. The image sensor with the spectrum sensor according to claim 1, wherein each of the light-detection part comprises:
a light-detection part for the image sensor region; and
a light-detection part for the spectrum sensor region.
6. The image sensor with the spectrum sensor according to claim 5,
wherein the image sensor region further comprises a color filter provided on each of the light-detection parts for the image sensor region.
7. The image sensor with the spectrum sensor according to claim 5,
wherein the spectrum sensor region further comprises a band pass filter provided on each of the light-detection parts for the spectrum sensor region.
8. The image sensor with the spectrum sensor according to claim 7, wherein a band width of light wavelength transmitting the band pass filter is 20 mn or less.
9. The image sensor with the spectrum sensor according to claim 8, wherein band widths of the plurality of the band pass filter overlap with each other.
10. The image sensor with the spectrum sensor according to claim 1, wherein the light-detection part is at least one selected from a group including a photodiode, a photo transistor and a photo conductor.